RxDoctor Payments Data

Shirley Simmons, PA

Medical · Clarksburg, WVNPI 1386678035

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AstraZeneca at 29.0% of the total. Reporting peaked in 2024 at $936 and has fallen 50.1% since, to $467 in 2025.

$3,135in general payments, 2019–2025

Across 148 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$910
  • GSK$759
  • Regeneron Healthcare Solutions, Inc.$501
  • Novartis$273
  • Genentech USA, Inc.$258
  • Sanofi$168
  • plus $265 from 7 others

What the payments were for

  • Food & beverage$3,129100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,135 in reported general payments places this provider in the 80th percentile of 233 medical providers in West Virginia.

See all medical providers in West Virginia

Medicare billing

Part B allowed, 2024
$11,012
Medicare patients
47
Services billed
874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,918
Advair HfaFluticasone Propion/Salmeterol18$5,876
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,283
Wixela InhubFluticasone Propion/Salmeterol14$2,170
Olopatadine Hcl12$1,342
Azelastine Hcl42$1,130
Fluticasone Propionate51$782
Montelukast Sodium37$523
Albuterol Sulfate HfaAlbuterol Sulfate12$442
Levocetirizine Dihydrochloride19$270
Azithromycin15$267
Famotidine16$77
Pantoprazole Sodium13$74
Prednisone12$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$759$11,91819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 233 medical providers in West Virginia.

Other medical in Clarksburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →